Table 1.
Baseline demographics and disease characteristics
| JNJ-78306358 Q1W SC dosing | Total (N = 39) | |||||||
|---|---|---|---|---|---|---|---|---|
| 46 µg (n = 7) | 15–46–90 µg (n = 6) | 15–90–270 µg (n = 5) | 15–46–180 µg (n = 5) | 15–90–180 µg (n = 5) | 15–46–270 µg (n = 5) | 15–46–180–225 µg (n = 6) | ||
| Age, mean (SD), y | 60.6 (9.98) | 64.3 (7.12) | 62.8 (15.99) | 64.4 (11.44) | 59.0 (10.84) | 59.2 (9.78) | 58.8 (2.86) | 61.3 (9.59) |
| Sex, n (%) | ||||||||
| Women, | 5 (71.4) | 5 (83.3) | 4 (80.0) | 2 (40.0) | 1 (20.0) | 5 (100.0) | 2 (33.3) | 24 (61.5) |
| Race, n (%) | ||||||||
| White | 6 (85.7) | 6 (100.0) | 4 (80.0) | 5 (100.0) | 5 (100.0) | 5 (100.0) | 6 (100.0) | 37 (94.9) |
| Unknown | 1 (14.3) | 0 | 1 (20.0) | 0 | 0 | 0 | 0 | 2 (5.1) |
| ECOG status, n (%) | ||||||||
| 0 | 7 (100.0) | 4 (66.7) | 4 (80.0) | 3 (60.0) | 3 (60.0) | 1 (20.0) | 5 (83.3) | 27 (69.2) |
| 1 | 0 | 2 (33.3) | 1 (20.0) | 2 (40.0) | 2 (40.0) | 4 (80.0) | 1 (16.7) | 12 (30.8) |
| Tumor type, n (%) | ||||||||
| RCC | 1 (14.3) | 1 (16.7) | 1 (20.0) | 1 (20.0) | 0 | 1 (20.0) | 1 (16.7) | 6 (15.4) |
| CRC | 3 (42.9) | 2 (33.3) | 4 (80.0) | 3 (60.0) | 5 (100.0) | 3 (60.0) | 3 (50.0) | 23 (59.0) |
| OC | 3 (42.9) | 3 (50.0) | 0 | 1 (20.0) | 0 | 1 (20.0) | 2 (33.3) | 10 (25.6) |
| Prior systemic therapies, n (%) | ||||||||
| 1 | 0 | 0 | 1 (20.0) | 0 | 1 (20.0) | 0 | 0 | 2 (5.1) |
| 2 | 2 (28.6) | 0 | 1 (20.0) | 0 | 2 (40.0) | 2 (40.0) | 0 | 7 (17.9) |
| 3 | 0 | 3 (50.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 1 (20.0) | 1 (16.7) | 9 (23.1) |
| ≥ 4 | 5 (71.4) | 3 (50.0) | 2 (40.0) | 4 (80.0) | 0 | 2 (40.0) | 5 (83.3) | 21 (53.8) |
CRC colorectal cancer; ECOG Eastern Cooperative Oncology Group; OC ovarian cancer; Q1W once every week; RCC renal cell carcinoma; SC subcutaneous; SD standard deviation